jcm-logo

Journal Browser

Journal Browser

Clinical and Interventional Therapeutic Advances of Acute Myocardial Infarction

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: closed (25 August 2025) | Viewed by 561

Special Issue Editors


E-Mail Website
Guest Editor
First Cardiology Department, University General Hospital AHEPA, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
Interests: PCI; intracoronary imaging; coronary artery disease; ACS; antiplatelet agents

E-Mail Website
Guest Editor
First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
Interests: PCI; CTO PCI; radial access; structural heart disease (TAVI, PFO)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are preparing a new Special Issue entitled ‘Clinical and Interventional Therapeutic Advances of Acute Myocardial Infarction’, scheduled to be published in the Journal of Clinical Medicine, and we would like to invite you to submit your research papers. Acute myocardial infarction remains a major cause of death and morbidity, despite progress in pharmacological and interventional treatments. New and more potent antiplatelet agents, new stent platforms, intracoronary imaging, calcium modification devices, and PPCI via snuffbox are some of the therapeutic advances we are experiencing in daily practice. Therefore, researchers in the field of interventional cardiology and treatment of acute myocardial infarction are invited to submit their research work, original articles, and reviews to this Special Issue.

Dr. Konstantinos C. Theodoropoulos
Prof. Dr. Antonios Ziakas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary artery disease
  • acute myocardial infarction
  • PPCI
  • antiplatelet agents
  • stents
  • radial access
  • snuffbox
  • intracoronary imaging
  • calcium modification
  • interventional thrombus modification

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1271 KB  
Article
The Prognostic Role of C-Reactive Protein Velocity in Patients with First Acute Myocardial Infarction
by Stylianos Daios, Vasileios Anastasiou, Dimitrios V. Moysidis, Matthaios Didagelos, Andreas S. Papazoglou, Christos Gogos, Nikolaos Stalikas, Efstratios Alexiadis, Konstantinos C. Theodoropoulos, Eleftheria Ztriva, Georgia Kaiafa, Kali Makedou, Vasileios Kamperidis, Antonios Ziakas and Christos Savopoulos
J. Clin. Med. 2025, 14(21), 7633; https://doi.org/10.3390/jcm14217633 - 28 Oct 2025
Viewed by 161
Abstract
Background/Objectives: Inflammation plays a key role in the pathophysiology of acute myocardial infarction (AMI). Yet static measures of C-reactive protein (CRP) provide limited prognostic information. CRP velocity (CRPv), which reflects the rate of CRP rise within the first 24 h, may better [...] Read more.
Background/Objectives: Inflammation plays a key role in the pathophysiology of acute myocardial infarction (AMI). Yet static measures of C-reactive protein (CRP) provide limited prognostic information. CRP velocity (CRPv), which reflects the rate of CRP rise within the first 24 h, may better depict the dynamic inflammatory response. To investigate the prognostic role of CRPv in patients presenting with a first AMI. Methods: Consecutive patients presenting with first AMI were enrolled. CRPv was calculated as the difference between CRP at admission and after 24 ± 8 h, divided by time. A prognostic CRPv cut-off was derived from spline curve analysis to dichotomize the population. Patients were followed up for the primary composite endpoint of cardiovascular death, non-fatal AMI, and hospitalization for heart failure. Results: Among 604 patients, 189 (31.3%) had CRPv ≥ 1.36 mg/L/h and 415 (68.7%) had CRPv < 1.36 mg/L/h. Higher hs-cTnT (adjusted odds ratio [aOR] 2.552, 95% CI, 1.520–4.286; p < 0.001) and NT-proBNP (aOR 2.229, 95% CI, 1.241–4.002; p = 0.007) were independently associated with CRPv ≥ 1.36 mg/L/h. At a median follow-up of 13.8 months, 115 patients (19.0%) reached the primary composite endpoint. High CRPv patients had significantly lower event-free survival rate than low CRPv patients (66.7% vs. 85.5%, log-rank p < 0.001). CRPv independently predicted the primary composite endpoint [adjusted hazard ratio 1.226, 95% CI 1.102–1.364, p < 0.001]. Adding CRPv on top of clinical, echocardiographic, and biochemical risk factors significantly improved model discrimination (p < 0.001), whereas single CRP on admission (p = 0.947) or CRP 24 ± 8 h from admission (p = 0.064) did not. Conclusions: CRPv appears to be a robust predictor of adverse outcomes in first AMI patients, offering incremental prognostic value beyond established clinical and biomarker indices. Its feasibility and low cost support its integration into early clinical risk stratification. Full article
Show Figures

Graphical abstract

Back to TopTop